Sökning: "alemtuzumab"

Visar resultat 1 - 5 av 10 avhandlingar innehållade ordet alemtuzumab.

  1. 1. lnduction Therapies in Multiple Sclerosis - Clinical and immunological follow-up

    Författare :Sofia Sandgren; Göteborgs universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Multiple Sclerosis; Neurodegeneration; Alemtuzumab; Autologous hematopoietic stem cell transplantation; Induction therapies Immune reconstitution therapies;

    Sammanfattning : Multiple sclerosis (MS) is a chronic disease that damages the central nervous system. Its pathophysiology is complex, and consists of inflammation and degeneration from the disease onset. The treatment of MS has continuously been developed with improved efficacy. LÄS MER

  3. 2. Targeted CD52 therapy in lymphoid malignancies : a clinical and immunological study

    Författare :Jeanette Lundin; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :CD52; alemtuzumab; Campath; monoclonal antibodies; chronic lymphocytic leukemia; non-Hodgkin s lymphoma; mycosis fungoides; immune suppression;

    Sammanfattning : There is a great need for developing new treatment alternatives in low grade non Hodgkin's lymphoma (NHL) including chronic lymphocytic leukemia (CLL). The CD52 antigen, which is expressed on almost all lymphoid malignancies, can be utilized as a target for CD52-directed monoclonal antibody therapy (alemtuzumab, Campath-1 H). LÄS MER

  4. 3. Targeted monoclonal antibody therapy in chronic lymphocytic leukemia

    Författare :Claes Karlsson; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Chronic lymphocytic leukemia (CLL) is still regarded as an incurable disease with a great need for developing new therapies and optimizing existing treatment options. The development of targeted therapy, i.e. therapy interfering with specific molecules needed for carcinogenesis and tumor growth, is rapidly evolving. LÄS MER

  5. 4. Targeted therapy and outcome in chronic lymphocytic leukemia

    Författare :Sandra Eketorp Sylvan; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Despite major advances, chronic lymphocytic leukemia (CLL) is still considered incurable. Fludarabine refractory patients and those with TP53disruptions have a particularly poor prognosis. Alemtuzumab is an established treatment option for these patients. However, its use is complicated by immunosuppressive side effects. LÄS MER

  7. 5. Targeted therapy in chronic lymphocytic leukemia

    Författare :Maria Winqvist; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature B lymphocytes in blood, bone marrow and lymphoid tissues. Historically, patients with TP53 aberration and with refractoriness to chemoimmunotherapy had a dismal prognosis. LÄS MER